Immatics Secures Four High-Profile Oral Slots for PRAME and Bispecific Programs at 2026 ASCO

Immatics ( (IMTX) ) has issued an announcement.

On April 21, 2026, Immatics announced that all four abstracts it submitted to the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting have been selected for oral presentations in Chicago, underscoring strong scientific visibility for its pipeline. The talks will cover Phase 1 data for lead PRAME-directed cell therapies anzu-cel (IMA203) and IMA203CD8 across melanoma, gynecologic cancers and synovial sarcoma, as well as first-in-human results for its MAGEA4/8 bispecific IMA401, highlighting continued advancement of its immunotherapy portfolio and potential to broaden its reach across diverse solid tumors.

The most recent analyst rating on (IMTX) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Immatics stock, see the IMTX Stock Forecast page.

Spark’s Take on IMTX Stock

According to Spark, TipRanks’ AI Analyst, IMTX is a Neutral.

The score is held back primarily by weak and volatile financial performance—especially ongoing cash burn and the sharp 2025 downturn—despite a comparatively strong, low-leverage balance sheet. Technicals are broadly neutral and do not offset the fundamental risk, while valuation support is limited given losses and no dividend.

To see Spark’s full report on IMTX stock, click here.

More about Immatics

Immatics N.V. is a biotechnology company focused on cancer immunotherapies, positioning itself as a global leader in precision targeting of PRAME, an antigen expressed in more than 50 cancer types. Its pipeline spans T-cell receptor (TCR) cell therapies and TCR bispecifics, forming a broad PRAME-focused franchise aimed at treating a wide range of solid tumors.

Average Trading Volume: 445,966

Technical Sentiment Signal: Buy

Current Market Cap: $1.47B

See more data about IMTX stock on TipRanks’ Stock Analysis page.